Investing
Turnarounds That Haven't Turned Around: Rite Aid (RAD, WAG, CVS, WMT)
Published:
Last Updated:
Rite Aid (NYSE:RAD) is a turnaround story that frankly has never ceased being a turnaround story. Can you remember the mid to late 1990’s stock trading? One great stock in the drug store arena that had a fresh look and feel was Rite Aid. But then in 1998 and 1999, this one went to hell in a hand basket. During the pinnacle it traded north of $40.00, but this entire decade has been the decade of wrong-aid. It hasn’t seen $10.00 the entire decade. It has made several recovery attempts and failed.
Its new Co-Chairman and President & CEO Marry Sammons is well thought of and deemed a winner for this company. Jim Cramer has been behind her naming this his #2 Speculative Pick for 2007 , as have other media pundits. This summer everything was seeming to go right at the company and the stock was above $6.00. The new plan was working on the surface. Then it posted a net loss and that was that. Shares have only moderately recovered after posting a slightly wider loss in September.
It recently lost its chief marketing officer in early November and its most recent same-store-sales have been moderately higher. With a $3.2 Billion market cap and expected sales north of $24 Billion, it is dirt cheap on a price/sales ratio. Even after a poor performance out of Walgreen’s (NYSE:WAG), its market cap is $36.5 Billion on an expected $60 Billion in annual sales.
So if Rite Aid can ever get the "E" back in its P/E this one has major room for upside. It’s just too bad that this has been the case every year in recent history. Maybe some turnarounds take longer than others in a competitive space, but some turnarounds at troubled companies seem to stay….. umm, troubled. There is always the argument that Wal-Mart’s (NYSE: WMT) new program and increased pressure from CVS Caremark (NYSE: CVS) are stronger than before, but at the end of the day the stock market players only want to own established companies that can prove they have steady earnings power and steady dependability. Rite Aid needs to consider this, even if it means a lower top-line.
Shares still sit around $4.00 and the 52-week low is $3.44. Rite Aid was just featured with a bit more detail in our "10 Stocks Under $10" weekly newsletter. This is also featured from time to time on our Open Email Dustribution List.
Jon C. Ogg
December 17, 2007
Jon Ogg can be reached at [email protected]; he produces the SPECIAL SITUATION newsletter and he does not own securities in the companies he covers.
If you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
Click here to download your FREE copy.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.